Targeted management of vascular anomalies
Journal of the European Academy of Dermatology and Venereology · 2026-05 · 40 (5) · 773-781
DOI: 10.1111/jdv.70151 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 28.10.2025. Verfasst von Jessie T Lu und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Clinical Medicine, University of New South Wales Medicine and Health, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Molecular Targeted Therapy, Signal Transduction, Vascular Malformations. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 61 Literaturangaben.
Abstract (Originalsprache)
Advances in genetic sequencing technology have enabled identification of the somatic and germline variants that underlie many vascular anomalies. These pathogenic variants often affect one of two signalling pathways: (1) the PI3K (phosphoinositide 3‐kinase)/AKT (protein kinase B)/mTOR (mammalian target of rapamycin) pathway and (2) the RAS (rat sarcoma)/RAF (rapidly accelerated fibrosarcoma)/MEK (mitogen‐activated protein kinase)/ERK (extracellular signal‐regulated kinase) pathway. This narrative review aims to synthesize the existing knowledge on the genetic origin of vascular anomalies and the targeted therapeutic approaches. A literature search was conducted using PubMed, Google Scholar and EMBASE, with a key focus on genetic pathways and emerging therapies. mTOR inhibitors have shown efficacy in a range of venous, lymphatic, capillary and syndromic vascular malformations. PIK3CA inhibitors are already commonly used in the treatment of PIK3CA ‐related overgrowth spectrum (PROS), with current research into new mutant‐specific inhibitors aiming to improve selectivity and reduce toxicity. AKT inhibitors are being trialled in Proteus syndrome and PROS. MEK inhibitors have shown efficacy in the treatment of capillary malformations with arteriovenous malformations (CM‐AVM) and both MEK and BRAF inhibitors are being investigated for use in extracranial AVMs. Vascular anomalies were previously orphan diseases with minimal effective therapeutic approaches. The discovery of the precise molecular pathways underlying these anomalies has allowed existing drugs to be repurposed for genotype‐guided management, enabling a ‘personalized’ approach to patient care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Clinical Medicine, University of New South Wales Medicine and Health, Sydney, New South Wales, Australia.
- The Skin Hospital, Sydney, New South Wales, Australia.
- Department of Dermatology, Liverpool Hospital, Liverpool, New South Wales, Australia.
ORCID-Profile: Jessie T Lu, Marra Aghajani, Deshan F Sebaratnam
Zitieren
APA
Lu, J. T., Aghajani, M., & Sebaratnam, D. F. (2026). Targeted management of vascular anomalies. Journal of the European Academy of Dermatology and Venereology, 40(5), 773-781. https://doi.org/10.1111/jdv.70151
Vancouver
Lu JT, Aghajani M, Sebaratnam DF. Targeted management of vascular anomalies. Journal of the European Academy of Dermatology and Venereology. 2026;40(5):773-781. doi:10.1111/jdv.70151
BibTeX
@article{Lu2026,
author = {Lu, Jessie T and Aghajani, Marra and Sebaratnam, Deshan F},
title = {Targeted management of vascular anomalies},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2026},
volume = {40},
number = {5},
pages = {773--781},
doi = {10.1111/jdv.70151}
}
EUVIMED